Search

everythinglearnresearchcommunity

for

Search:↓

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

User experienced hair growth after 1 year using Dut 0.5mg weekly, Min 2.5mg daily, and derma 1.5mm weekly. Hair became thicker, healthier, and hairline improved after adding derma rolling.

User shared 1-year progress on Fin 1 mg, switching to 0.4 mg Dut and oral 1.25 mg Min. Good results with Fin, biotin supplement, and biotin shampoo; trying Dut and oral Min for potential better results.

The user achieved impressive hair regrowth using 1mg finasteride and topical minoxidil, and is now adding dutasteride due to recent diffuse thinning. They experienced initial side effects with finasteride but no longer have issues.

Dutasteride 1.5 mg stopped shedding and reduced scalp inflammation in one month, unlike finasteride. The user also uses minoxidil but saw no results until adding dutasteride.

The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

The user is considering reducing their finasteride dose from 2.5mg to 1.25mg to make the supply last longer and is concerned about potential changes in results. They have been using the 2.5mg dose for four months.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

The user has been using 1.25mg of finasteride daily for one year to address hair loss. Progress pictures are included to show the results.

The user experienced significant hair regrowth using oral finasteride 1.25mg daily and a Capillus RX laser cap, with no side effects. Improvement was noticed after 9 months, and shedding stopped after the initial 4-5 months.

A user shared their 1.5-year experience using 0.25mg finasteride daily for hair loss, noting significant hair quality improvements and reduced scalp itch but mild erectile dysfunction. They managed side effects with daily 2.5mg Cialis and 5mg citrulline and plan to continue this routine.

User shared 1.5-year progress using 1mg finasteride, 15% minoxidil daily, and derma rolling weekly. Experienced initial shedding but achieved significant hair regrowth and improvement.

VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.

A user underwent a 2,550 FUE hair transplant and started taking dutasteride 0.5mg. They previously tried RU58841, minoxidil, and microneedling but avoided finasteride and dutasteride due to side effects.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A user's results after using finasteride (1.25mg/day) for one year, which included improvements to their hair and skin as well as some side effects such as decreased libido and watery semen. They also mentioned they stopped taking creatine around the same time.

The user shared impressive hair regrowth results after 1.5 years using dutasteride (DUT) and oral minoxidil. They switched from finasteride and topical minoxidil due to lack of results and experienced no side effects.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

The user has been using Finasteride 1mg daily for 13 years with stable results but is now experiencing thinning hair and is considering switching to Dutasteride 0.5mg. They are seeking advice on whether this change might be beneficial.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

User shared a 1-year update on finasteride, noting thicker hair but mild side effects like reduced libido and mild ED. Considering reducing the dose from 1mg to 0.5mg daily to alleviate side effects.

The conversation discusses the effectiveness of different doses of finasteride for hair loss, questioning the need for 1mg daily when 0.5mg every other day has a similar impact on scalp DHT. A humorous reply suggests exaggerated side effects.

A 21-year-old shares their one-year progress using finasteride for hair loss, experiencing initial shedding but eventual regrowth, especially on the crown. They consider switching to dutasteride due to continued hair loss at the front temple and mid-scalp areas.

The user "Bardo95" shared their one-year progress using finasteride (FIN) for hair loss. They experienced thickening of their general thinning and received compliments on their progress. Other users discussed their own experiences with finasteride and expressed hope for similar results.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

The conversation is about a user's one-year hair loss treatment using dutasteride, oral and topical minoxidil, ketoconazole, tretinoin, and PRP. Users discuss treatment effectiveness, potential issues with diffuse thinning, and sourcing affordable treatments.